G N F C (GNFC)

FairStock Score: 47/100 — MIXED

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Zero debt (D/E 0.00) provides strong financial stability and downside protection.
• Trading below book value at P/B 0.86, offering a margin of safety.
• Low P/E of 10.73 and dividend yield of 3.96% give income and reasonable valuation.
• Positive sales growth of 5.11% and promoter holding of 41.30% show some top-line resilience and alignment.
• Latest quarter net profit of ₹150 Cr on sales of ₹1,996 Cr indicates ongoing operations are profitable.

Concerns

• ROE of 7.45% and ROCE of 9.57% are weak, indicating poor capital efficiency.
• Profit growth is negative at -7.98%, and Piotroski F-Score of 4/9 suggests deteriorating financial health.
• Commodity chemical business lacks durable moat and pricing power; PEG of 2.10 implies no cheap growth.
• FairStock Score of 38/100 flags a mixed overall fundamental picture.

AI Analysis

At ₹481.95, GNFC offers the sort of quantitative bargain Graham would inspect, but Buffett would ask: what kind of business am I buying? The numbers tell me this is a commodity chemical producer, not a franchise with pricing power. Sales grew 5.11%, but profits fell 7.98%; the latest quarter's ₹150 Cr profit, annualised, is around ₹600 Cr, putting the P/E at 10.73. Book value is ₹562.47, so I am buying at 0.86 times book—a 14% discount. Zero debt is genuinely admirable; D/E of 0.00 means the balance sheet will not keep me awake at night. The 3.96% dividend yield is a real return while I wait. But I need more than cheapness. Return on equity is only 7.45%, and ROCE is 9.57%—both mediocre for a business exposed to chemical price cycles. A Piotroski F-score of 4/9 warns that the fundamentals are not improving. Profit is shrinking, and the 2.10 PEG ratio suggests the market is not giving me growth at a bargain price. There is no durable moat: commodity chemicals are price-takers. Promoter holding of 41.30% is decent alignment, but not enough to ignore weak economics. Would I put a large portion of my family's money here? Probably not. This is a cyclical, asset-backed business selling below book with a clean balance sheet. It is a candidate for further study, but only if chemical prices stabilise and returns on capital move toward double digits. Until then, I'd watch it, perhaps with a small position, and let Mr. Market offer a better price or better fundamentals.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer